PatrickM.ReaganMD

PubMed

• 3 citations
  Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
  Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwo...> ;Blood Advances. 2024 Feb 27
• 2 citations
  Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
  Mark Roschewski, Manish R Patel, Patrick M Reagan, Nakhle S Saba, Graham P Collins, Hendrik-Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen Burke, R...> ;Clinical Cancer Research. 2023 Sep 1
• Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
  Danielle S Wallace, Chris Rowland, Brian T Hill, Andrea M Baran, Carla Casulo, Patrick M Reagan, Allison Winter, Reem Karmali, Jane N Winter, Leo I Gordon, Andrew Bui,...> ;Leukemia & Lymphoma. 2023 Sep 1
• 11 citations
  ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.
  Yeonsun Hong, Brandon L Walling, Hye-Ran Kim, William S Serratelli, John R Lozada, Cooper J Sailer, Andrea M Amitrano, Kihong Lim, Raj Kumar Mongre, Kyun-Do Kim, Tara ...> ;Nature Immunology. 2023 Jun 1
• 2 citations
  Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.
  Kriti Thapa, Myla Strawderman, Patrick M Reagan, Paul M Barr, Clive S Zent, Jonathan W Friedberg, Tina Faugh, Carla Casulo> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
• 60 citations
  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
  Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abh...> ;Blood. 2023 May 11
• 4 citations
  Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
  Danielle S Wallace, Clive S Zent, Andrea M Baran, Patrick M Reagan, Carla Casulo, Geoffrey Rice, Jonathan W Friedberg, Paul M Barr> ;Blood Advances. 2023 Jun 13
• 1 citations
  PD-1CAR-T cells provide superior protection against solid tumors.
  Cooper J Sailer, Yeonsun Hong, Ankit Dahal, Allison T Ryan, Sana Mir, Scott A Gerber, Patrick M Reagan, Minsoo Kim> ;Frontiers in Immunology. 2023 Jan 1
• 60 citations
  Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...
  Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essel...> ;The Lancet. Oncology. 2022 Aug 1
• 33 citations
  Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
  Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo, Lorenzo Iovino, Ana Alarcon Tomas, Craig Sauter, Miguel-Angel Perales, Nirav N Shah, Utkarsh H...> ;Haematologica. 2023 Jan 1
• 82 citations
  Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
  Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A Mc...> ;Journal of Clinical Oncology. 2023 Jan 20
• 7 citations
  Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
  Miriam T Jacobs, Michael D Jain, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick M Reagan, Olalekan O O...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 3 citations
  Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
  R Andrew Harkins, Sharvil P Patel, Michelle J Lee, Jeffrey M Switchenko, Stephen M Ansell, Nancy L Bartlett, Kristie A Blum, Amanda F Cashen, Carla Casulo, Jonathan W ...> ;Blood Advances. 2022 May 10
• 44 citations
  Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.
  Naman Sharma, Patrick M Reagan, Jane L Liesveld> ;Cancers. 2022 Mar 15
• 449 citations
  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
  Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten, Olalekan O Oluwole, Armin Ghobadi, Aaron P Rapoport, Joseph McGuirk, Joh...> ;The New England Journal of Medicine. 2022 Feb 17
• 9 citations
  Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
  Bushra Tbakhi, Patrick M Reagan> ;Therapeutic Advances in Hematology. 2022 Jan 1
• 51 citations
  Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission.
  Mazyar Shadman, Marcelo C. Pasquini, Kwang Woo Ahn, Yue Chen, Cameron J. Turtle, Peiman Hematti, Jonathon B. Cohen, Farhad Khimani, Siddhartha Ganguly, Reid W. Merryma...> ;Blood. 2021 Sep 27
• 41 citations
  Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.
  Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluw...> ;Blood Advances. 2021 Oct 26
• 17 citations
  Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients with Lymphoma Treated with Chemotherapy.
  Michelle C. Janelsins, Mostafa R. Mohamed, Luke J. Peppone, Allison Magnuson, Elizabeth Belcher, Marianne Melnik, Shaker R. Dakhil, Jodi Geer, Charles Kamen, Lori M. M...> ;Journal of the National Cancer Institute. 2021 Jul 13
• 2 citations
  Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
  Danielle Wallace, Patrick M. Reagan> ;Drugs. 2021 Mar 30
• 15 citations
  Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
  Patrick M. Reagan, Jonathan W. Friedberg> ;Future Oncology. 2021 Jan 15
• 18 citations
  How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
  Patrick M. Reagan, Sattva S. Neelapu> ;Journal of Clinical Oncology. 2021 Jan 12
• 72 citations
  Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy
  Jay Y. Spiegel, Saurabh Dahiya, Michael D. Jain, John S. Tamaresis, Loretta J. Nastoupil, Miriam T. Jacobs, Armin Ghobadi, Yi Lin, Matthew A. Lunning, Lazaros J. Lekak...> ;Blood. 2020 Nov 6
• 1 citations
  Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
  Thomas D. Rodgers, AnnaLynn M. Williams, Andrea Baran, Patrick M. Reagan, Carla Casulo, Clive S. Zent, Andrew G. Evans, Jonathan W. Friedberg, Paul M. Barr> ;Leukemia & Lymphoma. 2021 Feb 23
• 211 citations
  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
  Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi...> ;Blood Advances. 2020 Oct 13
• Join now to see all

Abstracts/Posters

• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018